Crispr Therapeutics AG has expanded its in vivo pipeline with two new programs, which utilize lipid nanoparticle (LNP)-based delivery of CRISPR/Cas9 gene-editing cargo to the liver.
Suzhou Sanegene Bio Inc.’s clinical trial application for SGB-3908 injection, an siRNA drug for the treatment of hypertension, has been accepted in China by the National Medical Products Administration (NMPA)’s Center for Drug Evaluation (CDE).
About six months after Johnson & Johnson (J&J) returned rights to the compound, oral Tryvio (aprocitentan) won FDA clearance for Idorsia Ltd. Given once daily at a 12.5 mg dose, Tryvio is indicated for hypertension in combination with other blood pressure drugs in patients whose condition is not adequately controlled.
The RNAi therapeutic zilebesiran, which was the focus of a 2023 $2.8 billion deal between Alnylam Pharmaceuticals Inc. and Roche Holding AG, demonstrated significant systolic blood pressure reductions in patients with mild to moderate hypertension who were part of the Kardia-2 phase II study.
Shanghai-based Ji Xing Pharmaceuticals has signed a number of licensing deals over the last week for China rights to cardiovascular drugs to advance its pipeline and its global ambitions, partnering most recently with Tokyo-based TMS Co. Ltd. after the Chinese company acquired global rights for TMS-007 (also known as BIIB-131) from Biogen Inc.
Researchers from Shenzhen Salubris Pharmaceuticals Co. Ltd. have published preclinical data for the angiotensin receptor neprilysin (ARN) inhibitor S-086, currently in clinical development for the treatment of hypertension.
Shanghai-based Ji Xing Pharmaceuticals has signed a number of licensing deals over the last week for China rights to cardiovascular drugs to advance its pipeline and its global ambitions, partnering most recently with Tokyo-based TMS Co. Ltd. after the Chinese company acquired global rights for TMS-007 (also known as BIIB-131) from Biogen Inc.
Orchestra Biomed Holdings Inc. randomized the first patient in the BACKBEAT pivotal study investigating the use of its atrioventricular interval modulation (AVIM) therapy as a treatment for patients with uncontrolled hypertension implanted with a Medtronic plc pacemaker. AVIM therapy is an investigational patented bioelectronic therapy designed to immediately and durably reduce blood pressure.
Innovent Biologics Inc. and Sanegene Bio USA Inc. (Sanegenebio) have announced they have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen (AGT) for the treatment of hypertension.
Backbeat Medical Inc. is seeking patent protection for methods and systems for controlling blood pressure to either treat hypertension by using a first electrical stimulation pattern that reduces both systolic blood pressure and diastolic blood pressure.
